Big 3 PBM formularies favor private-label biosimilars
In 2025, the three largest pharmacy benefit managers are largely rejecting biosimilars from their formularies, with the exception of their own private-label medicines, Drug Channels reported Jan. 22. Humira (adalimumab), a popular immunosuppressive …